biosimilar
Biosimilar is a term used to describe medical products that are almost identical to an original product manufactured by a different company. Once the patent expires on the original product, referred to as the "innovator", biosimilars are allowed to be produced and can be approved for use.
What's Popular in biosimilar
MAR 18, 2021
9:00 AM PDT
C.E. CREDITS
MAR 18, 2021
9:00 AM PDT
Date: March 18, 2021 Time: 9:00am (PST), 12:00am (EST) As novel therapeutic modalities progress through development, improved analytical techniques are required to overcome characterization...
AUG 11, 2020
10:00 AM PDT
C.E. CREDITS
AUG 11, 2020
10:00 AM PDT
DATE: August 11, 2020 TIME: 10:00am PDT, 1:00pm EDT Biopharma researchers facing a difficult time adopting CE-SDS for purity/heterogeneity analysis of new protein modalities can now...
The NIST Biomanufacturing Program develops measurement science, standards, reference data and tools to support the development, manufacturing, and regulatory approval of biologic medicines....
OCT 25, 2018
9:00 AM PDT
OCT 25, 2018
9:00 AM PDT
Hydrogen-deuterium exchange mass spectrometry (HDX-MS) has developed into a powerful tool for investigating biopharmaceuticals, protein interactions, and membrane protein dynamics. Since 2010...
OCT 24, 2018
10:30 AM PDT
OCT 24, 2018
10:30 AM PDT
Two-dimensional (2D) 1H-13C methyl correlated NMR is increasingly being recognized as a powerful tool to characterize the higher order structure (HOS) of monoclonal antibody (mAb) therapeutic...
AUG 07, 2018
8:00 AM PDT
AUG 07, 2018
8:00 AM PDT
DATE: August 7, 2018TIME: 08:00AM PDT, 11:00AM EDTWe are currently at an exciting precipice in clinical oncology management, where an increased rate of biomarker identification is drivi...
MAR 24, 2017
7:30 AM PDT
MAR 24, 2017
7:30 AM PDT
DATE: March 24th, 2017TIME: 7:30AM PT, 10:30AM ET There is a growing demand in the biopharmaceutical industry for rapid N-glycosylation profiling of therapeutic antibodies....
FEB 20, 2017
8:00 AM PST
FEB 20, 2017
8:00 AM PST
Development of biosimilars for marketed bio-therapeutics is expected to increase patient access and affordability of these therapeutics within the healthcare system. One of the key aspe...
